Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rasagiline

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Rasagiline. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-005140-89 Sponsor Protocol Number: TVP-1012-120-TYR Start Date*: 2006-12-11
    Sponsor Name:TEVA Pharmaceuticals Industries Ltd
    Full Title: A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY S...
    Medical condition: This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011541-24 Sponsor Protocol Number: TVP-1012/501 Start Date*: 2009-10-09
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014644-11 Sponsor Protocol Number: MSA-RAS-202 Start Date*: 2009-12-08
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy o...
    Medical condition: Multiple System Atrophy of the Parkinsonian Subtype
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) IT (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001420-21 Sponsor Protocol Number: P2B001/003 Start Date*: 2018-06-18
    Sponsor Name:Pharma Two B Ltd
    Full Title: A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to...
    Medical condition: Early Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted)
    Trial results: View results
    EudraCT Number: 2005-001416-42 Sponsor Protocol Number: TVP-1012/500 Start Date*: 2005-09-15
    Sponsor Name:Teva Pharmaceuticals Industries LtD
    Full Title: A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10061536 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Completed) ES (Completed) AT (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013004-31 Sponsor Protocol Number: RASA-ROPI Start Date*: 2009-11-02
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI PARMA
    Full Title: Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study inc...
    Medical condition: Patients with Parkinson`s diesease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004482-32 Sponsor Protocol Number: RAS-ALS Start Date*: 2013-04-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023756-82 Sponsor Protocol Number: TUD-RaSPar-051 Start Date*: 2011-07-13
    Sponsor Name:Dresden University of Technology
    Full Title: Rasagiline treatment for Sleep disorders in Parkinson´s disease
    Medical condition: sleep disturbances/sleep disorders in patients with Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015162-57 Sponsor Protocol Number: P06153 Start Date*: 2011-03-02
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) SE (Prematurely Ended) BG (Completed) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007397-28 Sponsor Protocol Number: 2007-007397-28 Start Date*: 2008-08-06
    Sponsor Name:Qualissima
    Full Title: Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce
    Medical condition: Maladie de Parkinson idiopathique au stade précoce Maladie de Parkinson, numéro de classification MedDRA 10061536
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015161-31 Sponsor Protocol Number: P04938 Start Date*: 2010-08-17
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) FR (Completed) NL (Completed) ES (Completed) AT (Completed) DE (Completed) IT (Completed) SE (Completed) PT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-007520-26 Sponsor Protocol Number: PROSPERA (Rasagiline) Start Date*: 2010-06-24
    Sponsor Name:Klinikum der Universität München
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)
    Medical condition: Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004530-33 Sponsor Protocol Number: 3337541 Start Date*: 2006-04-12
    Sponsor Name:Oy Lundbeck
    Full Title: Rasagiliinin ja essitalopraamin yhteiskäytön turvallisuus
    Medical condition: terveet vapaaehtoiset
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-011144-19 Sponsor Protocol Number: 12962A Start Date*: 2009-11-19
    Sponsor Name:LUNDBECK ITALIA
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate if rasagiline can improve depressive symptoms and cognitive function in non-demented, idiopathic Parkinson s disease patients.
    Medical condition: Subjects will be recruited from the Movement Disorders Outpatient Clinics from academic and hospital institutions in Italy. Only subjects with a BDI-IA score > or = 15 at baseline will be enrolled....
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004400-12 Sponsor Protocol Number: FIRHSCSP/07/14 Start Date*: 2007-12-27
    Sponsor Name:Institut de Recerca de l'Hospital de la santa Creu i Sant Pau
    Full Title: ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA
    Medical condition: Apatía en la Enfermedad de Parkinson
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000973-19 Sponsor Protocol Number: SWH-MAOB Start Date*: Information not available in EudraCT
    Sponsor Name:IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
    Full Title: OVERNIGHT SWITCH FROM RASAGILINE TO SAFINAMIDE IN FLUCTUATING PATIENTS WITH PARKINSON’S DISEASE: A TOLERABILITY AND SAFETY STUDY
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000335-17 Sponsor Protocol Number: MPR001 Start Date*: 2014-10-28
    Sponsor Name:Research and Development University Hospital of North Staffordshire [...]
    1. Research and Development University Hospital of North Staffordshire
    2. Keele University
    Full Title: The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment
    Medical condition: Idiopathic Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013552-72 Sponsor Protocol Number: P05664 Start Date*: 2010-09-07
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005085-30 Sponsor Protocol Number: TUD-Olfact-035 Start Date*: 2009-04-06
    Sponsor Name:Technische Universität Dresden
    Full Title: Einfluss von Rasagilin auf das Riechvermögen von Patienten mit idiopathischem Parkinson-Syndrom (Reversibility of olfactory loss in patients with Idiopathic Parkinson’s disease following treatme...
    Medical condition: Idiopathic Parkinson syndrome (IPS), State according to Hoehn & Yahr: maximum III
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10034008 Parkinson's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003679-31 Sponsor Protocol Number: 2015_22 Start Date*: 2016-04-06
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease
    Medical condition: De Novo Parkinson’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) CZ (Completed) PT (Completed) FR (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 15:33:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA